Previous 10 | Next 10 |
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC’s national provider network, providing enhanced care to their approximate...
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42 nd Annual Growth Stock Conference, which takes place June 6-9, 2022, in Chicago at the Loews Chi...
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered service with Alivio Health, providing enhanced care to their 150,000 membe...
The following slide deck was published by Exagen Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Exagen Inc. 2022 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Exagen Inc. (NASDAQ: XGN) Q1 2022 Earnings Call May 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Exagen Inc. (XGN) Q1 2022 Earnings Call Transcript
Exagen Inc. (XGN) Q1 2022 Earnings Conference Call May 11, 2022 16:30 ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Mark Hazeltine - Chief Operating Officer Conference Call Participants Brian W...
Exagen press release (NASDAQ:XGN): Q1 GAAP EPS of -$0.60 beats by $0.01. Revenue of $10.4M (-1.9% Y/Y) beats by $0.4M. For further details see: Exagen GAAP EPS of -$0.60 beats by $0.01, revenue of $10.4M beats by $0.4M
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has provided pricing for AVISE ® Lupus. Noridian’s decision to price AV...
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2022. First Quarter Highlights: Generated total revenue of $10.4 million for ...
SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to...
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...